|
|||||
|
|
| 恩杂鲁胺在晚期前列腺癌患者中的应用 | |
| 引用本文： | 张鑫,武进峰,康云鹏. 恩杂鲁胺在晚期前列腺癌患者中的应用[J]. 临床泌尿外科杂志, 2014, 0(9): 838-841 |
| 作者姓名： | 张鑫 武进峰 康云鹏 |
| 作者单位： | 山西医科大学;山西医科大学附属山西大医院泌尿外科; |
| 摘 要： | 通过搜索Pubmed以及ClinicalTrials.gov数据库,包括ASCO会议摘要,回顾恩杂鲁胺的前瞻性临床试验及其结果:恩杂鲁胺对于去势抵抗性前列腺癌是一种有效的口服药,在化疗前和化疗后患者中均生存期获益,毒性温和,并获得NICE最终指南推荐用于治疗多西他赛化疗后的转移性去势抵抗性前列腺癌(mCRPC)患者。本文就其有关方面情况作一综述。 |
| 关 键 词： | 恩杂鲁胺 雄激素受体 转移性前列腺癌 去势抵抗 多西他赛耐药性 |
Use of enzalutamide in the patients with advanced prostate cancer |
|
| Affiliation: | ZHANG Xin WU Jinfeng KANG Yunpeng (1Shanxi Medical University, Taiyuan, 030001, China; 2Department of Urology, Shanxi Dayi Hospital of Shanxi Medical University) |
| Abstract: | By searching Pubmed and ClinicalTrials. gov databases, including ASCO （American Society of Clinical Oncology） meeting abstract, prospective clinical trials and results of enzalutamide were reviewed. Enzalutamide is an effective oral therapy for castration-resistant prostate cancer. It may offer survival benefit before and following chemotherapy, and toxicity is mild. Moreover, the National Institute for Health and Care Excellence （NICE） issues final draft guidance recommends enzalutamide should be used for metastatic castration-resistant prostate cancer （mCRPC） after docetaxel chemotherapy. This＇review briefly introduces latest progress of enzalutamide for advanced prostate cancer. |
| Keywords: | enzalutamide androgen receptor metastatic prostate cancer castration-resistant docetaxel resistance |
| 本文献已被 CNKI 维普 等数据库收录！ | |